z-logo
open-access-imgOpen Access
Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer
Author(s) -
Okusaka Takuji,
Ikeda Masafumi,
Fukutomi Akira,
Ioka Tatsuya,
Furuse Junji,
Ohkawa Shinichi,
Isayama Hiroyuki,
Boku Narikazu
Publication year - 2014
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12501
Subject(s) - folfirinox , medicine , oxaliplatin , gastroenterology , neutropenia , irinotecan , chemotherapy , pancreatic cancer , regimen , febrile neutropenia , phases of clinical research , fluorouracil , nausea , clinical endpoint , surgery , cancer , colorectal cancer , clinical trial
The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine the efficacy and safety of FOLFIRINOX in chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer. FOLFIRINOX (i.v. infusion of 85 mg/m 2 oxaliplatin, 180 mg/m 2 irinotecan, and 200 mg/m 2  l ‐leucovorin, followed by a bolus of 400 mg/m 2 fluorouracil and a 46‐h continuous infusion of 2400 mg/m 2 fluorouracil) was given every 2 weeks. The primary endpoint was the response rate. The 36 enrolled patients received a median of eight (range, 1–25) treatment cycles. The response rate was 38.9% (95% confidence interval [ CI ], 23.1–56.5); median overall survival, 10.7 months (95% CI , 6.9–13.2); and median progression‐free survival, 5.6 months (95% CI , 3.0–7.8). Major grade 3 or 4 toxicities included neutropenia (77.8%), febrile neutropenia (22.2%), thrombocytopenia (11.1%), anemia (11.1%), anorexia (11.1%), diarrhea (8.3%), nausea (8.3%), elevated alanine aminotransferase levels (8.3%), and peripheral sensory neuropathy (5.6%). Febrile neutropenia occurred only during the first cycle. There were no treatment‐related deaths. FOLFIRINOX can be a standard regimen showing favorable efficacy and acceptable toxicity profile in chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here